BAQSIMI 3 mg, powder nasal in a single-dose container single-dose container
Active ingredients: Glucagon
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Powdersingle-dose containernasale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- BAQSIMI 3 mg, poudre nasale en récipient unidose
- Pharmaceutical form
- poudre
- Route of administration
- nasale
- Presentation description
- 1 récipient(s) unidose(s) polyéthylène polypropylène
- Marketing authorisation holder
- AMPHASTAR FRANCE PHARMACEUTICALS
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Oct 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67972497CIP73019529CIP133400930195291Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLUCAGONpoudre | 3 mg · une dose | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.